Clonit announces the acquisition of Dia.Pro – Diagnostic Bioprobes expanding its reach in advanced diagnostics
Clonit is proud to announce the acquisition of Dia.Pro, a strategic milestone that strengthens our position in the global in-vitro diagnostics landscape.
This integration marks a significant step forward in expanding our product portfolio, enhancing technological capabilities, and accelerating our long-term vision: delivering high-quality, reliable, and innovative diagnostic solutions worldwide.
Dia.Pro’s expertise in immunodiagnostics and high-quality assay development perfectly complements Clonit’s strong focus on molecular diagnostics. Together, we are building a more comprehensive, agile, and future-ready offering that responds to the evolving needs of clinical laboratories and healthcare professionals.
This acquisition reinforces our commitment to scientific excellence, operational reliability, and continuous innovation — ensuring that our partners can count on a broader range of solutions, a stronger support network, and a rapidly expanding international presence.
For more details, please refer to the official press release available below.